30 closest matches · ranked by relevance
Liver Transplantation · Surgical Site Infection
Primary: Number of Subjects With Development of Surgical Site Infections — 9; 13 Participants
BK Virus Infection
Primary: Number of Patients Developing BK Infection at 6 Months Post-transplant — 25; 5 Participants
Kidney Transplant
Primary: The Difference Between the Mean eGFR (Modified MDRD) in the Experimental vs. Control Groups. — 52.45; 57.35 mL/min/1.73m2 — p=0.099
Hypogammaglobulinemia · Lung Transplantation
Primary: Number of Clinically Diagnosed Bacterial Infections During the Treatment Period — 3; 1 Infections
Infections After Lung Transplant
Primary: The Primary Outcome Will be the Total Number of Days With Pneumonia. — 1714; 51 Number of days
Hepatitis C · Cirrhosis
Primary: HCV RNA Result — 924,082; 3,731,749 IU/ml
Prophylaxis Of Invasive Fungal Infections
Primary: Occurrence of Proven or Probable Invasive Fungal Infection (IFI): Start of Prophylaxis Until 12-month Follow-up Visit — 3 participants
Diabetes · End Stage Renal Disease
Primary: Incidence of Poor Graft Function After Kidney Transplant — 13; 22 Participants
Infection
Primary: Number of Patients Where a Suitable VST Line Could be Found — 80 Participants
BK Viremia · BK Nephropathy
Primary: Number of Participants With BK Viral Load <600 Copies/mL — 13; 17 Participants
Antifungal Prophylaxis of Invasive Fungal Infections
Primary: Success at Day 180: Percent of Responders (Randomization Strata) — 59.1; 44.7; 52.5; 25.9 percent of participants
Liver Transplant
Primary: Infection Rates — 27; 26; 11; 7 Participants — p=0.841
Liver Transplant · Liver Transplantation
Primary: Proportion of Participants Successfully Withdrawn From Immunosuppression — 0.60 Proportion of participants
Lung Diseases
Primary: Subject Sustained Virologic Response (SVR-12) at 12-weeks Post-treatment — 10 Participants
Poor Thymic Function · Immunodeficiency · Athymia
Primary: Survival Rate at End of 1 Year — 90.9 percentage of participants
BK Virus (BKV) Viremia
Primary: Incidence of BKV Viremia in the Study Population of Screened Renal or Renal-pancreas Transplant Subjects — 58 Participants
Nonmalignant Breast Conditions · Breast Cancer
Primary: Number of Subjects With Drain Bulb Fluid Bacterial Colonization at Approximately 1 Week — 10; 21 participants — p=0.02
Lung Transplant Infection
Primary: Number of Participants Free From New or Progressive Chronic Lung Allograft Dysfunction — 2; 4 Participants
End Stage Renal Disease · Hepatitis C
Primary: Viral Response at Week 12 — 10 Participants
Acute Lymphoblastic Leukemia · Acute Myelogenous Leukemia · Chronic Myelogenous Leukemia
Primary: Antibody Recall Response Rate — 0.167 proportion of participants
Kidney Failure
Primary: Serum Creatinine Concentration — 112 umol/L
Inherited Immune Deficiencies
Primary: Stem Cell Transplant Engraftment — 7; 31; 3; 0 Participants
Chronic Granulomatous Disease
Primary: Percentage of Participants With Engraftment — 100 percentage of participants
Fusariosis · Onychomycosis
Primary: Proportion of Patients Who Develop Invasive Fusariosis Until Neutrophil Recovery — 6; 8 Participants
Hepatitis C · Transplantation Disease Transmission
Primary: Proportion of Participants With HCV RNA Level Below Limits of Quantification (LOQ) — 23 Participants
Hodgkin Disease · Non-Hodgkin Lymphoma · Multiple Myeloma
Primary: Incidence of Clinically Significant Bacteremia — 3; 9 participants
Kidney Transplantation · Diabetes · Hyperglycemia
Primary: Delayed Graft Function — 8; 12 participants
Cytomegalovirus
Primary: Number of Participants With a Complete Response — 8; 50 Participants
Complete DiGeorge Anomaly · DiGeorge Syndrome · DiGeorge Anomaly
Primary: Survival Rate at End of 1 Year — 79.3 percentage of participants
Renal Transplant Infection
Primary: Participants Will Experience Less BK Infection Episodes Based on Viruria Results.